Organic Active Ingredients TRIZ Cases

Formula Im1 derivatives selectively inhibit 11β-HSD1 to reduce systemic side effects while improving insulin sensitivity and glucose tolerance.

Segmented fractional lobe screws balance radial and lateral shear rates to eliminate stagnation points in pharmaceutical continuous manufacturing.

Embedding the carrier peptide within a liposome membrane prevents carrier antibody interference, ensuring high specificity for diagnostic assays.

Heteroaryl-methyl substituted triazoles act as selective vasopressin receptor v1a antagonists.

Local quality modifications on heteroaryl pyrimidine scaffolds resolve selectivity challenges against other kinases.

Chiral titanium complex catalyzes asymmetric oxidation of pro-chiral sulphides, achieving 99% enantiomeric excess for treating gastric disorders.

A dietary supplement combines melatonin, GABA, and herbal extracts to promote restorative sleep through synergistic physiological pathways.

Fluorine modification of Formula I compounds boosts systemic drug concentration while maintaining selective CDK8 and CDK19 inhibition.

Aminothiolester compounds increase hydrogen peroxide levels in cancer cells to trigger apoptosis.

Triazolopyridin-3-one derivatives suppress vascular adhesion protein-1 to reduce leukocyte infiltration in nonalcoholic steatohepatitis.

Switching from hydrochloride to hydrobromide salt reduces anxiety, agitation, and insomnia while improving therapeutic efficacy.

Specific compounds bind the KRAS G12C cysteine residue, inhibiting mutant protein activity and overcoming resistance in pancreatic and colorectal cancers.

PCSK9 inhibitors bypass slow synthesis pathways to rapidly lower triglycerides, resolving acute pancreatitis severity and duration.

Solvent migration creates non-tacky, stable THC particles with high encapsulation efficiency for pharmaceutical use.

Selective CB2 receptor agonists combined with steroids modulate innate immune responses to reduce inflammatory damage.

N-substituted indenoisoquinolines replace unstable camptothecin lactone rings with heteroaryl groups to prevent enzyme recovery and enhance anticancer efficacy.

Freeze-thaw extraction removes water-soluble impurities while organic solvent steps eliminate liposoluble contaminants for medicinal-grade purity.

Grignard-Tamao and fluoride salt routes address stereo-specificity bottlenecks in benzoxazepin oxazolidinone synthesis.

Formula I compounds bind CFTR proteins to stabilize folded conformations, correcting trafficking defects that cause cystic fibrosis.

Biodegradable drug depots release alpha and beta adrenergic agonists via PLGA polymer matrices to provide sustained localized analgesia.

Bosutinib inhibits Chk1 and Wee1 kinases to override cell cycle arrest, enhancing cancer cell sensitivity to DNA damage-induced death.

Prodrugs deliver sinapic acid O-glucoside or neoliquiritin to reduce Aβ fibrillization and tau aggregation, addressing marginal relief in existing therapies.

Overexpressing A622, NBB1, PMT, and QPT genes resolves the contradiction between reducing harmful smoke components and maintaining high nicotine content.

Formula IA heterocyclic compounds block MAGL activity, reducing neuroinflammation and pain by regulating endocannabinoid levels.

Acetylated peptides disrupt the Heparanase Tissue Factor complex, resolving solubility limitations of current anticoagulants.

Adding sialylated and fucosylated human milk oligosaccharides to infant formula reduces cortical and trabecular porosity while increasing bone mineral density.

Indolylacetic derivatives inhibit TNF-alpha and iNOS without affecting COX-2, addressing insufficient ALS treatment efficacy.

Pre-implantation factor peptides reduce neuro-inflammation and protect motor neurons, addressing the limited efficacy of current riluzole therapies.

Cereblon-binding compounds degrade IKZF2 via the CRL4 ligase complex, avoiding systemic T-effector activation.

Acetylsalicylic acid dimers block the C3 convertase stage to prevent membrane attack complex formation and reduce tissue damage in mammals.

Compounds of Structure I inhibit NEK7 to modulate NLRP3 inflammasome activity.

Phenyl-indole allosteric modulators enhance G protein signaling at cannabinoid receptors to treat neuropathic pain while minimizing psychoactive side effects.

Direct compression of aminocarboxylic acid salts with D-mannitol and carmellose calcium prevents degradation during storage.

Sulfamide compounds mitigate oxidative stress to prevent neuronal damage in neurodegenerative disorders.

N-acetyl-L-cysteine zinc chelate overcomes poor mineral absorption by forming stable rings that cross the blood-brain barrier.

Sulfobutyl ether beta-cyclodextrin forms an inclusion complex with meloxicam to overcome poor aqueous solubility and improve bioavailability.

Metal-based coordination complexes inactivate immunogens via photoexcitation, restoring vaccine efficacy in immunocompromised patients.

Segmented granulation maintains stable 5-HTP release profiles after 24 months storage, preventing gastrointestinal disorders.

A three-step synthesis method for DHPV using epoxide ring-opening and oxidative cleavage to produce antioxidants.

Modulating CCR3 receptors via eotaxin-1 interaction mitigates synapse loss and slows cognitive decline.

Targeting PARP9 and PARP14 resolves the contradiction between immune protection and chronic inflammation by regulating macrophage activation pathways.

Specific siRNA and ASO oligonucleotides target HGFAC to overcome inadequate therapeutic efficacy and suboptimal clinical responses in current cancer treatments.

Substituted 1,3,4-thiadiazole compounds inhibit glutaminase 1 to disrupt cancer cell metabolism.

An effervescent tablet formulation using citric acid and sodium bicarbonate to resolve brivaracetam adhesion and stability issues.

Plant-derived extracellular vesicles resolve particle size consistency issues by specifying precise diameter ranges and targeted RNA sequences.

Modified halogen groups and carbon chain lengths enhance differentiation efficiency while reducing production costs.

Fructose analogs target the glycolytic pathway to inhibit cancer cell proliferation while minimizing harm to normal cells.

L-histidine crosses the blood-brain barrier to increase central histamine levels, bypassing peripheral conversion limits that hinder direct histamine therapy.

Curved DNA strands form a toroidal pore that overcomes tubular structure limits, enabling high-speed lipid scrambling.

Anti-LAG3 antibodies antagonize immune suppression by blocking LAG3 binding to MHC class II molecules, enhancing T-cell activation.

A Garcinol-cyclodextrin complex normalizes cardiac function parameters and reduces oxidative stress.

Modified oligonucleotides reduce Factor XII protein levels through targeted hybridization, preventing thromboembolic events without increasing bleeding risk.

Iridium(III) complexes with N-heterocyclic carbene ligands deliver potent cytotoxicity against tumor cells under light irradiation.

Electrochemical biosensing platform detects coronavirus spike protein binding to ACE2 receptors on host cells.

Niacinamide triggers keratinocyte activation to produce antimicrobial peptides, addressing inadequate natural skin defense against pathogens.

A biocompatible polymer implant releases antiviral agents through diffusion to maintain therapeutic concentrations over several months.

Oral ferric citrate formulation manages iron-deficiency anemia while reducing adverse side effects and reliance on invasive intravenous treatments.

Ginsenoside Rd formulation resolves gastric and organ damage trade-offs by modulating the NF-κB pathway for safe acute and chronic inflammation treatment.

Carbon-nitride dot nanocarriers conjugated with doxorubicin and transferrin facilitate targeted cellular uptake.

Trigonelline inhibits spike protein-induced lipid deposition and ferroptosis, preserving cell viability under obesity conditions.

Combining lutein with vitamin K derivatives stabilizes collagen concentration in tissues through synergistic antioxidant action.

Shear-thinning fluid gel compositions resolve limited chemical tunability by enabling programmable release mechanisms for ocular therapies.

Substituted indole compounds block TLR7, 8, and 9 to reduce inflammatory responses in autoimmune diseases.

Merges CD19 and BTK inhibitors to disrupt tumor microenvironment signaling, enhancing efficacy against hematological malignancies.

A lenalidomide tablet with a protective film layer resolves capsule bulkiness and drug exposure risks by ensuring safe handling and easy swallowing.